Montelux (Montelukast Sodium)

Montelukast sodium selectively blocks the cysteinyl leukotriene receptor CysLT1, preventing leukotriene D4 from causing bronchoconstriction and inflammation, which helps keep the airways open and reduces allergic responses.

The appropriate dose of Montelux is determined by a qualified prescriber based on the patient’s age, weight, condition severity, and clinical response. Dosage instructions are provided on the prescription label.

Safety data for montelukast sodium in pregnancy are limited, and the product is classified as pregnancy category unknown. Women who are pregnant, planning pregnancy, or breastfeeding should discuss potential risks and benefits with their healthcare professional.

To request Montelux, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Montelux belongs to the leukotriene receptor antagonist class, offering an oral alternative to inhaled corticosteroids or long‑acting beta‑agonists. It targets leukotriene‑mediated inflammation, which can be complementary to other controller medications, especially for patients who prefer oral therapy.

Montelux should be stored at ambient temperature, below 25 °C, in its original packaging. Keep the tablet container tightly closed and protect it from moisture and direct sunlight.

Montelux is taken orally, usually once daily in the evening, with or without food, as directed by the prescribing clinician. Swallow the tablet whole; do not crush or chew it.

Serious adverse reactions, although rare, can include angioedema, severe allergic reactions, mood alterations such as depression, and suicidal thoughts. Patients should seek immediate medical attention if they experience any of these symptoms.

Montelux should be avoided in individuals with a known hypersensitivity to montelukast sodium or any of the tablet’s excipients. Patients with severe hepatic impairment should also be evaluated carefully before use.